{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:31:05Z","timestamp":1788517865364,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The linear ubiquitin chain assembly complex (LUBAC) has been implicated in both cancer progression and viral activity; however, its role in the progression of hepatitis B virus (HBV)-associated hepatocellular carcinoma (HBV-HCC) remains unclear. Here we found that the expression of LUBAC components and Met1-linked ubiquitination was significantly upregulated and associated with poor prognosis in HCC; however, blocking the LUBAC activity with HOIPIN-1 did not affect the malignancy of HCC cells or their sensitivity to sorafenib treatment. Targeting HOIL-1 inhibited the progression of HCC in vitro and in vivo. Interestingly, we found that\n                    <jats:italic>HOIL-1<\/jats:italic>\n                    , but not other LUBAC components, was exclusively upregulated in HBV-HCC. Functionally, HOIL-1 knockdown suppressed tumor growth, metastasis and stemness in HBV-infected HCC cells. Mechanistically, HOIL-1 interacted with HBx, but not other HBV proteins, and facilitated its stabilization by recruiting deubiquitinatinase USP15, thereby reducing HBx K48-linked ubiquitination. Notably, the clinical analysis indicated that the association between high HOIL-1 expression and poor prognosis was evident only in patients with HBV-HCC with high USP15 expression and not in those with low USP15 expression. Collectively, our results demonstrated that HOIL-1 acts as an oncogene to promote HBV-HCC progression independent of LUBAC activity and may serve as a potential therapeutic target for HBV-HCC.\n                  <\/jats:p>","DOI":"10.1038\/s12276-025-01556-4","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:55:01Z","timestamp":1759744501000},"page":"2317-2330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The LUBAC subunit HOIL-1 promotes the progression of HBV-associated hepatocellular carcinoma independently of linear ubiquitination"],"prefix":"10.1038","volume":"57","author":[{"given":"Zheyu","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyue","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoting","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-3600","authenticated-orcid":false,"given":"Yuchuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0667-5311","authenticated-orcid":false,"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7060-2953","authenticated-orcid":false,"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-7642","authenticated-orcid":false,"given":"Yongyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"1556_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"1556_CR2","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","volume":"64","author":"M Levrero","year":"2016","unstructured":"Levrero, M. & Zucman-Rossi, J. Mechanisms of HBV-induced hepatocellular carcinoma. J. Hepatol. 64, S84\u2013S101 (2016).","journal-title":"J. Hepatol."},{"key":"1556_CR3","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3390\/v14050986","volume":"14","author":"GEM Rizzo","year":"2022","unstructured":"Rizzo, G. E. M., Cabibbo, G. & Craxi, A. Hepatitis B virus-associated hepatocellular carcinoma. Viruses 14, 986 (2022).","journal-title":"Viruses"},{"key":"1556_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.canlet.2017.02.003","volume":"392","author":"S Zhang","year":"2017","unstructured":"Zhang, S. et al. Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein. Cancer Lett. 392, 94\u2013104 (2017).","journal-title":"Cancer Lett."},{"key":"1556_CR5","first-page":"630","volume":"123","author":"X Xu","year":"2013","unstructured":"Xu, X. et al. Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J. Clin. Invest. 123, 630\u2013645 (2013).","journal-title":"J. Clin. Invest."},{"key":"1556_CR6","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.omtn.2022.08.008","volume":"29","author":"H Liu","year":"2022","unstructured":"Liu, H. et al. Circular RNA circSFMBT2 downregulation by HBx promotes hepatocellular carcinoma metastasis via the miR-665\/TIMP3 axis. Mol. Ther. Nucleic Acids 29, 788\u2013802 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1556_CR7","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/hep.29316","volume":"66","author":"Y Gao","year":"2017","unstructured":"Gao, Y. et al. Hepatitis B virus X protein-elevated MSL2 modulates hepatitis B virus covalently closed circular DNA by inducing degradation of APOBEC3B to enhance hepatocarcinogenesis. Hepatology 66, 1413\u20131429 (2017).","journal-title":"Hepatology"},{"key":"1556_CR8","doi-asserted-by":"publisher","first-page":"8832","DOI":"10.1093\/nar\/gky589","volume":"46","author":"YY Lee","year":"2018","unstructured":"Lee, Y. Y. et al. Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis. Nucleic Acids Res. 46, 8832\u20138847 (2018).","journal-title":"Nucleic Acids Res."},{"key":"1556_CR9","doi-asserted-by":"publisher","first-page":"7231","DOI":"10.1128\/JVI.73.9.7231-7240.1999","volume":"73","author":"Z Hu","year":"1999","unstructured":"Hu, Z. et al. Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex. J. Virol. 73, 7231\u20137240 (1999).","journal-title":"J. Virol."},{"key":"1556_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.625169","volume":"11","author":"T Wan","year":"2021","unstructured":"Wan, T. et al. NEDD4 induces K48-linked degradative ubiquitination of hepatitis B virus X protein and inhibits HBV-associated HCC progression. Front. Oncol. 11, 625169 (2021).","journal-title":"Front. Oncol."},{"key":"1556_CR11","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00611-22","volume":"96","author":"Q Wu","year":"2022","unstructured":"Wu, Q. et al. Hepatitis B virus X protein is stabilized by the deubiquitinating enzyme VCPIP1 in a ubiquitin-independent manner by recruiting the 26S proteasome subunit PSMC3. J. Virol. 96, e0061122 (2022).","journal-title":"J. Virol."},{"key":"1556_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/hep.1840140106","volume":"14","author":"WL Wang","year":"1991","unstructured":"Wang, W. L., London, W. T., Lega, L. & Feitelson, M. A. HBxAg in the liver from carrier patients with chronic hepatitis and cirrhosis. Hepatology 14, 29\u201337 (1991).","journal-title":"Hepatology"},{"key":"1556_CR13","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.3390\/v6114683","volume":"6","author":"MM Minor","year":"2014","unstructured":"Minor, M. M. & Slagle, B. L. Hepatitis B virus HBx protein interactions with the ubiquitin proteasome system. Viruses 6, 4683\u20134702 (2014).","journal-title":"Viruses"},{"key":"1556_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrc.2017.105","volume":"18","author":"D Senft","year":"2018","unstructured":"Senft, D., Qi, J. & Ronai, Z. A. Ubiquitin ligases in oncogenic transformation and cancer therapy. Nat. Rev. Cancer 18, 69\u201388 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"1556_CR15","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1038\/sj.emboj.7601360","volume":"25","author":"T Kirisako","year":"2006","unstructured":"Kirisako, T. et al. A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J. 25, 4877\u20134887 (2006).","journal-title":"EMBO J."},{"key":"1556_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41556-020-0517-9","volume":"22","author":"Y Fuseya","year":"2020","unstructured":"Fuseya, Y. et al. The HOIL-1L ligase modulates immune signalling and cell death via monoubiquitination of LUBAC. Nat. Cell Biol. 22, 663\u2013673 (2020).","journal-title":"Nat. Cell Biol."},{"key":"1556_CR17","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nature09814","volume":"471","author":"F Ikeda","year":"2011","unstructured":"Ikeda, F. et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-\u03baB activity and apoptosis. Nature 471, 637\u2013641 (2011).","journal-title":"Nature"},{"key":"1556_CR18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41418-020-00676-w","volume":"28","author":"AS Jahan","year":"2021","unstructured":"Jahan, A. S., Elbaek, C. R. & Damgaard, R. B. Met1-linked ubiquitin signalling in health and disease: inflammation, immunity, cancer, and beyond. Cell Death Differ. 28, 473\u2013492 (2021).","journal-title":"Cell Death Differ."},{"key":"1556_CR19","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/HEP.0000000000000623","volume":"80","author":"P Chen","year":"2024","unstructured":"Chen, P. et al. Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for hepatocellular carcinoma. Hepatology 80, 330\u2013345 (2024).","journal-title":"Hepatology"},{"key":"1556_CR20","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/s12276-020-0461-6","volume":"52","author":"P Chen","year":"2020","unstructured":"Chen, P. et al. Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation. Exp. Mol. Med. 52, 1062\u20131074 (2020).","journal-title":"Exp. Mol. Med."},{"key":"1556_CR21","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.bbrc.2018.12.164","volume":"509","author":"K Katsuya","year":"2019","unstructured":"Katsuya, K. et al. Small-molecule inhibitors of linear ubiquitin chain assembly complex (LUBAC), HOIPINs, suppress NF-\u03baB signaling. Biochem. Biophys. Res. Commun. 509, 700\u2013706 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1556_CR22","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41420-022-01126-x","volume":"8","author":"X Chen","year":"2022","unstructured":"Chen, X. et al. RBCK1 promotes hepatocellular carcinoma metastasis and growth by stabilizing RNF31. Cell Death Discov. 8, 334 (2022).","journal-title":"Cell Death Discov."},{"key":"1556_CR23","first-page":"1372","volume":"12","author":"Z Xu","year":"2022","unstructured":"Xu, Z. et al. The E3 ubiquitin ligase RBCK1 promotes the invasion and metastasis of hepatocellular carcinoma by destroying the PPAR\u03b3\/PGC1\u03b1 complex. Am. J. Cancer Res. 12, 1372\u20131392 (2022).","journal-title":"Am. J. Cancer Res."},{"key":"1556_CR24","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41590-022-01290-3","volume":"23","author":"M Musella","year":"2022","unstructured":"Musella, M. et al. Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B. Nat. Immunol. 23, 1379\u20131392 (2022).","journal-title":"Nat. Immunol."},{"key":"1556_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3845","volume":"15","author":"L Zitvogel","year":"2015","unstructured":"Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405\u2013414 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"1556_CR26","doi-asserted-by":"publisher","first-page":"17862","DOI":"10.1073\/pnas.0608578103","volume":"103","author":"LR Huang","year":"2006","unstructured":"Huang, L. R., Wu, H. L., Chen, P. J. & Chen, D. S. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc. Natl Acad. Sci. USA 103, 17862\u201317867 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1556_CR27","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jhep.2012.04.020","volume":"57","author":"L Xia","year":"2012","unstructured":"Xia, L. et al. Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma. J. Hepatol. 57, 600\u2013612 (2012).","journal-title":"J. Hepatol."},{"key":"1556_CR28","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s12072-022-10351-6","volume":"16","author":"L Yang","year":"2022","unstructured":"Yang, L. et al. Hepatitis B virus X protein mediated epigenetic alterations in the pathogenesis of hepatocellular carcinoma. Hepatol. Int 16, 741\u2013754 (2022).","journal-title":"Hepatol. Int"},{"key":"1556_CR29","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1016\/j.celrep.2019.11.041","volume":"29","author":"G Tan","year":"2019","unstructured":"Tan, G. et al. Type-I-IFN-stimulated gene TRIM5\u03b3 inhibits HBV replication by promoting HBx degradation. Cell Rep. 29, 3551\u20133563.e3 (2019).","journal-title":"Cell Rep."},{"key":"1556_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/srep40246","volume":"7","author":"ZJ Su","year":"2017","unstructured":"Su, Z. J. et al. Deubiquitylation of hepatitis B virus X protein (HBx) by ubiquitin-specific peptidase 15 (USP15) increases HBx stability and its transactivation activity. Sci. Rep. 7, 40246 (2017).","journal-title":"Sci. Rep."},{"key":"1556_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/ncb1821","volume":"11","author":"F Tokunaga","year":"2009","unstructured":"Tokunaga, F. et al. Involvement of linear polyubiquitylation of NEMO in NF-\u03baB activation. Nat. Cell Biol. 11, 123\u2013132 (2009).","journal-title":"Nat. Cell Biol."},{"key":"1556_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2016.76","volume":"5","author":"Y Tanaka","year":"2016","unstructured":"Tanaka, Y. et al. Sharpin promotes hepatocellular carcinoma progression via transactivation of Versican expression. Oncogenesis 5, e277 (2016).","journal-title":"Oncogenesis"},{"key":"1556_CR33","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1164\/rccm.201403-0463OC","volume":"190","author":"MA Queisser","year":"2014","unstructured":"Queisser, M. A. et al. HOIL-1L functions as the PKC\u03b6 ubiquitin ligase to promote lung tumor growth. Am. J. Respir. Crit. Care Med 190, 688\u2013698 (2014).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"1556_CR34","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1038\/s41388-022-02485-6","volume":"41","author":"Y Guo","year":"2022","unstructured":"Guo, Y. et al. Linear ubiquitination of PTEN impairs its function to promote prostate cancer progression. Oncogene 41, 4877\u20134892 (2022).","journal-title":"Oncogene"},{"key":"1556_CR35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/imr.12307","volume":"266","author":"L Elton","year":"2015","unstructured":"Elton, L., Carpentier, I., Verhelst, K., Staal, J. & Beyaert, R. The multifaceted role of the E3 ubiquitin ligase HOIL-1: beyond linear ubiquitination. Immunol. Rev. 266, 208\u2013221 (2015).","journal-title":"Immunol. Rev."},{"key":"1556_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.semcancer.2020.05.002","volume":"67","author":"P Wang","year":"2020","unstructured":"Wang, P., Dai, X., Jiang, W., Li, Y. & Wei, W. RBR E3 ubiquitin ligases in tumorigenesis. Semin. Cancer Biol. 67, 131\u2013144 (2020).","journal-title":"Semin. Cancer Biol."},{"key":"1556_CR37","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.3892\/or.2014.3425","volume":"32","author":"X Lu","year":"2014","unstructured":"Lu, X., Ye, K., Zou, K. & Chen, J. Identification of copy number variation-driven genes for liver cancer via bioinformatics analysis. Oncol. Rep. 32, 1845\u20131852 (2014).","journal-title":"Oncol. Rep."},{"key":"1556_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jhep.2021.08.010","volume":"76","author":"K Sekiba","year":"2022","unstructured":"Sekiba, K. et al. HBx-induced degradation of Smc5\/6 complex impairs homologous recombination-mediated repair of damaged DNA. J. Hepatol. 76, 53\u201362 (2022).","journal-title":"J. Hepatol."},{"key":"1556_CR39","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/hep.31313","volume":"73","author":"GW Kim","year":"2021","unstructured":"Kim, G. W. et al. HBV-induced increased N6-methyladenosine modification of PTEN RNA affects innate immunity and contributes to HCC. Hepatology 73, 533\u2013547 (2021).","journal-title":"Hepatology"},{"key":"1556_CR40","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1053\/j.gastro.2013.10.056","volume":"146","author":"Y Okamoto","year":"2014","unstructured":"Okamoto, Y. et al. Hepatitis virus infection affects DNA methylation in mice with humanized livers. Gastroenterology 146, 562\u2013572 (2014).","journal-title":"Gastroenterology"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01556-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01556-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01556-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:04:02Z","timestamp":1762297442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01556-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["1556"],"URL":"https:\/\/doi.org\/10.1038\/s12276-025-01556-4","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Equal contribution statement has been updated.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}